L

Lumos Diagnostics Holdings Ltd
ASX:LDX

Watchlist Manager
Lumos Diagnostics Holdings Ltd
ASX:LDX
Watchlist
Price: 0.038 AUD 2.7% Market Closed
Market Cap: 28.4m AUD
Have any thoughts about
Lumos Diagnostics Holdings Ltd?
Write Note

Lumos Diagnostics Holdings Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lumos Diagnostics Holdings Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
L
Lumos Diagnostics Holdings Ltd
ASX:LDX
EPS (Diluted)
$0
CAGR 3-Years
42%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
EPS (Diluted)
AU$0
CAGR 3-Years
10%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
EPS (Diluted)
AU$0
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
6%
Anteris Technologies Ltd
ASX:AVR
EPS (Diluted)
-AU$4
CAGR 3-Years
-19%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
EPS (Diluted)
$0
CAGR 3-Years
-32%
CAGR 5-Years
-6%
CAGR 10-Years
8%
No Stocks Found

Lumos Diagnostics Holdings Ltd
Glance View

Market Cap
28.4m AUD
Industry
Health Care

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX Intrinsic Value
0.169 AUD
Undervaluation 78%
Intrinsic Value
Price
L

See Also

What is Lumos Diagnostics Holdings Ltd's EPS (Diluted)?
EPS (Diluted)
-0 USD

Based on the financial report for Jun 30, 2024, Lumos Diagnostics Holdings Ltd's EPS (Diluted) amounts to -0 USD.

What is Lumos Diagnostics Holdings Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
8%

Over the last year, the EPS (Diluted) growth was 50%. The average annual EPS (Diluted) growth rates for Lumos Diagnostics Holdings Ltd have been 42% over the past three years , 8% over the past five years .

Back to Top